Screener
Neurocrine Biosciences NBIX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $959M+39.5% | $814.5M+42.2% | $805.5M+28.3% | $794.9M+27.8% | $687.5M+16.5% | ||
| $23.2M+105% | $13.8M+50.0% | $17.6M+89.2% | $14M+75.0% | $11.3M+22.8% | ||
| $935.8M+38.4% | $800.7M+42.1% | $787.9M+27.4% | $780.9M+27.2% | $676.2M+16.4% | ||
| 97.6%-0.8pp | 98.3%-0.1pp | 97.8%-0.7pp | 98.2%-0.5pp | 98.4%-0.1pp | ||
| $326.7M+33.7% | $296.2M+12.5% | $258.2M+39.1% | $250M+28.2% | $244.3M+27.8% | ||
| $439.7M+53.6% | $318.5M+15.2% | $301.8M+4.9% | $291.6M+24.5% | $286.3M+18.3% | ||
| $807.5M+49.0% | $621.1M+13.1% | $594.6M+22.4% | $555.9M+26.8% | $541.9M+21.8% | ||
| $151.5M+4.1% | $193.4M+719% | $210.9M+48.5% | $239M+30.0% | $145.6M+0.1% | ||
| 15.8%-5.4pp | 23.7%+19.6pp | 26.2%+3.6pp | 30.1%+0.5pp | 21.2%-3.5pp | ||
| $10.7M-23.0% | $53.4M+700% | $28.5M— | $52.8M+712% | $13.9M+130% | ||
| $162.2M+1.7% | $246.8M+1,579% | $239.4M+47.2% | $291.8M+53.3% | $159.5M+61.8% | ||
| $17.8M-65.8% | $48.9M+619% | $85.7M+44.0% | $82.3M+36.0% | $52M+54.8% | ||
| $144.4M+34.3% | $197.9M+2,405% | $153.7M+49.1% | $209.5M+61.4% | $107.5M+65.4% | ||
| 15.1%-0.6pp | 24.3%+22.9pp | 19.1%+2.7pp | 26.4%+5.5pp | 15.6%+4.6pp | ||
| $1.39+31.1% | $1.91+2,287% | $1.48+48.0% | $2.04+64.5% | $1.06+68.3% | ||
| $176.3M+15.3% | $200.7M+543% | $218.4M+46.5% | $246.7M+29.6% | $152.9M+0.1% | ||
| 18.4%-3.9pp | 24.6%+19.2pp | 27.1%+3.4pp | 31%+0.4pp | 22.2%-3.6pp | ||
| $151.5M+4.1% | $193.4M+719% | $210.9M+48.5% | $239M+30.0% | $145.6M+0.1% |
FAQ
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.4B in revenue over the trailing twelve months, up 34.4% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $705.5M in net income over the trailing twelve months, a 20.9% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.0% and operating margin is 23.6%, with a 20.9% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.82.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
